Background and Purpose-The optimal approach to recanalization in acute ischemic stroke is unknown. We performed a literature review and meta-analysis comparing the relative efficacy of 6 reperfusion strategies: (1) 0.9 mg/kg intravenous tissue-type plasminogen activator; (2) intra-arterial chemical thrombolysis; (3) intra-arterial mechanical thrombolysis; (4) intra-arterial combined chemical/mechanical thrombolysis; (5) 0.6 mg/kg intravenous tissue-type plasminogen activator and intra-arterial thrombolysis; and (6) 0.9 mg/kg intravenous tissue-type plasminogen activator and intra-arterial thrombolysis. Methods-A literature search in Medline, Embase, and the Cochrane database identified case series, observational studies, and treatment arms of randomized trials of anterior circulation arterial occlusion treated with thrombolytic therapy. Included studies had Ն10 subjects, mean time to treatment Ͻ6 hours, and treatment specific reporting of disability, death, and intracerebral hemorrhage. Multivariable metaregression evaluated the effects of treatment group on outcome at the same time as accounting for differences in baseline covariates. Results-A total of 2986 abstracts were identified from which 54 studies (5019 subjects) were included. There were significant differences across groups in age (Pϭ0.0008), baseline National Institutes of Health Stroke Scale (Pϭ0.0002), and time to treatment initiation (PϽ0.0001). There were also differences in mean modified Rankin Scale (PϽ0.0001), mortality (Pϭ0.0024), and symptomatic intracerebral hemorrhage (Pϭ0.0305). Differences in modified Rankin Scale were not significant in the metaregression and likely attributable to differences in baseline covariates between studies. Conclusions-This study found no evidence that one reperfusion strategy is superior with respect to efficacy or safety, supporting clinical equipoise between reperfusion strategies. Intravenous tissue-type plasminogen activator remains the standard of care for acute ischemic stroke. Randomized clinical trials are necessary to determine the efficacy of alternative reperfusion strategies. Participation in such trials is strongly recommended. (Stroke. 2012;43:00-00.)
S troke is the fourth leading cause of death in the United
States and a leading cause of disability. 1 Stroke due to large-artery occlusion has a particularly poor prognosis with higher rates of death and disability than other stroke subtypes. [2] [3] [4] Current acute ischemic stroke interventions attempt to recanalize occluded arteries thereby restoring cerebral blood flow and improving functional outcome. The most well studied of these therapies is intravenous (IV) tissue-type plasminogen activator (tPA). Alternative strategies are available and have been used in both clinical practice and clinical research, including intra-arterial (IA) thrombolysis (chemical/ mechanical) and combined IVϩIA thrombolysis; however, the relative efficacy of these approaches is unknown. [5] [6] [7] [8] IV tPA is recommended as the first-line therapy for patients with acute ischemic stroke presenting within 4.5 hours of symptom onset. 9, 10 Unfortunately, recanalization rates with IV tPA are low when a large-artery occlusion is present with rates ranging from 4% to 68% depending on the study and the location of the occlusion. [11] [12] [13] A recent meta-analysis found a 46% recanalization rate overall with IV tPA. 14 Small studies suggest that endovascular thrombolysis may be a feasible alternative to IV tPA, although high-quality data on safety and efficacy are lacking. [15] [16] [17] [18] IA thrombolysis is associated with significantly higher rates of recanalization than IV tPA with reported rates exceeding 80%. 6, 8, 14, 19 However, with IA approaches, there is a tradeoff in delayed time to treatment, which may lessen the potential advantage because time to treatment is a major predictor of outcome after acute stroke. 9, 20 Combining IV and IA therapy has a theoretical advantage by merging rapid treatment initiation with IV tPA to IA techniques with high recanalization rates.
There are several clinical trials exploring the role of endovascular thrombolysis in acute stroke ( 21 There is a wide range of potential endovascular interventions including mechanical thrombectomy, combined IA chemical and mechanical thrombectomy, and IV tPA followed by IA therapy. It is unlikely that a clinical trial comparing all of these therapeutic approaches will be performed. To explore potential differences in the safety and efficacy of these methods, we used metaanalytic techniques to pool data from the literature and compare 6 different treatment approaches in subjects with a large-artery occlusion of the anterior circulation: (1) 0.9 mg/kg IV tPA; (2) IA chemical thrombolysis; (3) IA mechanical thrombolysis; (4) IA chemical and mechanical thrombolysis combined; (5) 0.6 mg/kg IV tPA followed by IA thrombolysis; and (6) 0.9 mg/kg IV tPA followed by IA thrombolysis. A better understanding of the relative safety and efficacy of these methods will help to guide future clinical trial design.
Methods

Literature Search
Articles were identified by searching Medline, EMBASE, and the Cochrane Central Register of Controlled Trials for reports of thrombolysis with occlusion of an anterior circulation artery (internal carotid artery, middle cerebral artery, anterior cerebral artery). Search terms are listed in online-only Data Supplement Table I . Search parameters were limited to English language, human studies, and publication from 1990 to February 2010. Searches were independently conducted by 2 of the authors. Abstracts for all results were reviewed and relevant studies were selected for further review. The references of included studies, review articles, and meta-analyses were also screened for relevant studies. The detailed search strategy is reported in online-only Data Supplement Table I .
Inclusion/Exclusion Criteria
Case series, observational studies, and treatment arms of randomized trials were included based on the following criteria: Ն10 subjects, treatment-specific reporting of death, symptomatic intracranial hemorrhage (sICH), and disability. For studies of IV tPA in which vascular imaging was not required, a hyperdense middle cerebral artery was considered diagnostic of middle cerebral artery occlusion. Studies were excluded if the mean time to treatment was Ͼ6 hours or if the majority of patients were included in another study already in the analysis. Studies that included a small number of subjects with occlusion of a posterior circulation artery (vertebral artery, basilar artery) were included if the number of posterior circulation occlusions comprised Ͻ25% of the total number of subjects. Studies that involved multiple interventions were included if outcomes were reported separately by treatment group or if there was one dominant treatment approach that was administered to Ն75% of the subjects. Case reports, editorials, letters, commentaries, and review articles were excluded.
Treatment Groups
We divided treatment interventions into 6 groups. Group 1 studies used IV tPA with alteplase at a dose of 0.9 mg/kg up to 4.5 hours after stroke onset. Studies using other thrombolytic drugs and dosing regimens were excluded. Group 2 studies used chemical thrombolysis with IA alteplase, urokinase, or reteplase but did not allow mechanical thrombectomy. Group 3 studies used mechanical thrombectomy alone (guidewire clot maceration, Merci/Multi-Merci device, Penumbra device, balloon angioplasty, and/or stent). Group 4 studies used mechanical thrombolysis in combination with chemical thrombolysis with IA alteplase, urokinase, or reteplase. Group 5 studies used IV tPA with alteplase at a dose of 0.6 mg/kg followed by IA chemical and/or mechanical thrombolysis. Group 6 studies used IV tPA with alteplase at a dose of 0.9 mg/kg followed by IA chemical and/or mechanical thrombolysis.
Data Extraction
The total number of subjects, treatment method, mean year of subject recruitment, mean and SD (or median and interquartile range) of National Institutes of Health Stroke Scale (NIHSS) scores, age, and time to treatment initiation, clinical outcome, mortality rate, and sICH rate were extracted from each study. When reported, the proportion of subjects with hypertension, diabetes mellitus, and atrial fibrillation were also recorded. Each study was independently reviewed by 2 of the investigators. Discordances between reviewers prompted adjudication by a third investigator. For studies involving multiple interventions for which treatment-specific outcome measures were reported, each relevant arm was analyzed separately. Thus, one study may provide data for more than one treatment group. Baseline stroke severity was assessed using the NIHSS. Time to treatment initiation was defined as duration, in minutes, from the onset of symptoms to the initiation of thrombolysis. For patients who received combined IVϩIA therapy, time to treatment initiation was calculated based on the start of IV tPA. Disability was assessed at 90 days in most studies and measured using the modified Rankin Scale (mRS) in 51 of 54 studies. In one study 22 (nϭ137), disability was reported using the Barthel Index (BI) grouped into mild (BI Ͼ90), moderate (BI 50 -90), and severe disability (BI Ͻ50), which were assigned mRS of 0.5, 2.5, and 4.5, respectively. Another study 23 (nϭ24) reported outcome using the BI as favorable (BI Ն95) or not, which was converted to a mRS of 0.5 and 3.5, respectively. Finally, one study 24 (nϭ67) reported outcome based on discharge disposition. For this study, subjects discharged to home were assigned a mRS of 0.5; all others were assigned 3.5. Symptomatic ICH was defined according to the individual study. For articles that reported sICH using multiple definitions, sICH was defined as clinical deterioration causing death or a Ն4-point increase in NIHSS. 25 Studies that did not report a clinical definition of sICH were included if the radiographic characteristics of the hemorrhage were reported. In these cases, sICH was defined as parenchymal hematoma Type 2 because prior studies suggest that these are clinically relevant hemorrhages. 26 Two studies differentiated hemorrhagic infarcts from parenchymal hematomas but did not differentiate hemorrhagic infarct Type 1 from hemorrhagic infarct Type 2 or parenchymal hematoma Type 1 from parenchymal hematoma Type 2 3 (total nϭ176, total sICHϭ17). In these studies, all parenchymal hematomas were assumed to be symptomatic.
Data Analysis
When a standard deviation of a study was not specifically reported, it was estimated from the reported interquartile range or the data range. 27, 28 For prevalence data such as mortality rate, we used the standard normal method to estimate SDs. 27 Our primary end point was the mean mRS score for each study. Where an interval of mRS scores was reported for a group of subjects such as 3 to 5, we used linear interpolation and scored the group as 4. The mRS is an ordered scale that is typically dichotomized in studies of acute stroke ("good" outcome variably defined as mRS Ͻ2, Ͻ3, or rarely Յ3; all others assigned a "poor" outcome). The linearity assumption allowed us to compare means using parametric statistical methods; however, it should be noted that prior work has shown the mRS to be nonlinear. 29 -31 
Statistical Analysis
Data from multiple studies were tested for homogeneity and pooled meta-analytically using inverse variance weighting and random effects models. 32, 33 We tested the effect of treatment type on survival, overall mRS, mRS of survivors, and incidence of sICH. Monte Carlo methods were used to generate simulated data that had the same means and distributions as the resulting pooled data. 34 Analyses of variance followed by post hoc analysis with Scheffe adjustment was done to compare outcomes in the simulated data for each treatment. 35 Metaregression was used to test the influence of treatment type, year of subject recruitment, baseline NIHSS, time to treatment initiation, and other baseline covariates on outcome. 36 In a post hoc analysis, studies with posterior circulation stroke were excluded and the analysis was repeated. Additionally, the proportion of subjects with a good clinical outcome (mRS Յ2) was compared across treatment groups. For this analysis, studies were excluded if they reported mRS scores in a way that prevented dichotomization. All statistical analyses were performed using Stata Version 12 (StataCorp, College Station, TX). We considered differences for which the probability value was Ͻ0.05 to be significant.
Results
Study Characteristics
A total of 2986 abstracts were identified from the literature search, from which 265 potential studies were identified for detailed review. Fifty-four studies, consisting of 5019 subjects, were included in the final analysis ( Figure) . Of these studies 20 of 54 (37%) were retrospective, 27 of 54 (50%) were prospective, and 7 of 54 (13%) could not be categorized. Some studies contributed to more than one treatment group. Detailed study characteristics are presented in online-only Data Supplement Table II . The majority of subjects received full-dose IV tPA (Group 1; nϭ2450), IA chemical thrombolysis alone (Group 2; nϭ1143), or IA mechanical and chemical thrombolysis in combination (Group 4; nϭ819).
Patient Characteristics
Pooled results are summarized in the Table. Mean Baseline NIHSS ranged from 15.9 (Group 2) to 20.1 (Group 3). These differences were significant (Pϭ0.0002) with Group 3 NIHSS scores significantly higher than all others (PϽ0.05). Mean time to treatment initiation ranged from 133 minutes (Group 5) to 258 minutes (Group 3) with significant differences between groups (PϽ0.0001). Treatment time was significantly longer in Group 3 than all others (PϽ0.05). Group 2 was higher than Group 1 (PϽ0.01). Treatment time for Group 4 was significantly longer than in Groups 1 (PϽ0.001) and 6 (PϽ0.009). Mean age among treatment groups varied from 59.7 years in Group 2 to 67.1 years in Group 4 (Pϭ0.0008). Patients in Group 2 were significantly younger than those in Groups 1 and 4 (Pϭ0.012 and 0.008, respectively).
Patient Outcomes
There were significant (PϽ0.0001) differences in mean mRS across treatment groups. Mean mRS was lower in Group 5 than Groups 1, 2, 3, and 4 (Pϭ0.0005, 0.020, 0.004, and 0.006, respectively). Mortality ranged from 17.1% in Group 6% to 40% in Group 3 (Pϭ0.0024). In pairwise comparisons, Group 3's mortality rate was significantly higher than that of Group 1 (Pϭ0.023). When mean mRS scores of survivors were examined (PϽ0.0001), Group 1 did less well than Group 5 (Pϭ0.001) and Group 2 (Pϭ0.004). Intergroup differences with regard to the incidence of sICH were significant (Pϭ0.0305), but there were no significant pairwise differences. In a post hoc analysis excluding studies with posterior circulation strokes, there were no significant differences between groups (Pϭ0.43; see online-only Data Supplement Table III ). In the dichotomized analysis, there were no significant pairwise differences in the proportion of subjects with a good outcome (mRS Յ2) across treatment groups (PϾ0.05) despite a significant intergroup difference (PϽ0.001; see online-only Data Supplement Table IV) .
Metaregression
The apparent superiority of mean mRS scores in Group 5 when compared with Groups 1 to 4 was no longer significant after 
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Discussion
This meta-analytic review found no evidence that one reperfusion strategy is superior with respect to efficacy or safety, supporting clinical equipoise between reperfusion strategies. 37 There were observed differences among the 6 different treatment groups with respect to functional outcome and mortality. However, metaregression showed that the observed differences in outcome were likely attributable to differences between groups on baseline covariates such as NIHSS and time to initiation of treatment and not due to a treatment effect. NIHSS and time to treatment initiation are known predictors of outcome after acute ischemic stroke. Accounting for these variables in the metaregression eliminated the observed differences in outcome across groups. We did not find a higher incidence of death or sICH with combined IVϩIA approaches (Groups 5 and 6). This finding is consistent with previous studies. A pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi-MERCI trials found that treatment with IV tPA before mechanical thrombectomy did not increase sICH rates when compared with treatment with mechanical thrombectomy alone. 38 A meta-analysis comparing low-dose IV tPA followed by IA thrombolysis with full-dose IV tPA followed by IA thrombolysis reported sICH rates in both groups, which were similar to those found in the National Institute of Neurological Disorders and Stroke IV tPA trial. 7, 39 The present study adds significantly to the existing literature by comparing combined IVϩIA thrombolysis to a wider variety of alternative therapeutic approaches. Given the theoretical advantage of combined IVϩIA thrombolysis and the observed clinical equipoise, combined IVϩIA thrombolysis is a logical target for future acute stroke trials. The use of endovascular therapy for acute stroke is being tested in several ongoing and/or future trials including IMS-III, MR CLEAN, MR Rescue, PISTE, and the Synthesis-EXP trial.
Our study has several important limitations. This study represents a series of indirect, nonrandomized comparisons using data from case series and observational cohort studies. There is significant clinical heterogeneity between treatment groups in this study. Studies varied with respect to patient selection, baseline severity, and time to treatment. Studies also differed methodologically with designs ranging from case series to randomized trials. Multiple agents were used for IA chemical thrombolysis and mechanical thrombolysis was broadly defined. This clinical heterogeneity resulted in significant statistical heterogeneity, which is only partially compensated for by our use of a random effects model. A metaregression was performed to investigate factors underlying the observed heterogeneity. Differences in time to treatment and baseline stroke severity are at least partially responsible for the variations between groups. This metaregression used trial-level data rather than individual subject data. This may introduce aggregation bias, although the observed relationships among time, baseline stroke severity, and mRS are consistent with published studies using patient-level data. 9,40 -42 Publication bias, a failure to publish small negative studies, may be affecting our results. We did not include unpublished studies in this meta-analysis because there was no reliable way to identify such studies. We attempted to create funnel plots for each treatment group, although the relatively small number of studies in each groups limited the applicability and interpretation of these plots. Nonetheless, it should be recognized that this meta-analysis may overestimate the efficacy of some interventions and the results must be interpreted with caution. We used linear interpolation and parametric methods to compare mean mRS scores across treatments, although the mRS is not an interval scale. The post hoc dichotomized analysis failed to detect significant pairwise differences across treatment groups, supporting our overall conclusion; nonetheless, a more sophisticated nonparametric analysis would be informative if patient-level data were available. The use of the hyperdense middle cerebral artery sign to identify studies for the IV treatment group may bias the estimates for Group 1 if hyperdense thrombi differ from thrombi which are isodense in response to therapy. Finally, there were widely differing definitions of sICH in the included studies, which could introduce bias. Some studies included in this analysis reported outcomes pooled across multiple types of treatments. These studies were included in the analysis only if there was a dominant treatment type, which was used in Ͼ75% of subjects. This potential misclassification affected 4 of the 54 studies and 116 of the 5019 total subjects. The bias introduced by this small amount of misclassification is unlikely to significantly alter our results. The decision to include studies in which vertebral basilar stroke was present in Ͻ25% of subjects could introduce bias given the poor prognosis associated with acute basilar occlusion. Most studies had a small number of vertebrobasilar occlusions. In total, 190 of 5019 subjects had a vertebrobasilar occlusion (7 in Group 1, 103 in Group 2, 5 in Group 3, 51 in Group 4, 8 in Group 5, 16 in Group 6). The analysis was repeated after exclusion of these studies and there was no statistically significant difference across treatment groups in mean mRS.
Summary/Conclusions
This study provides information on the relative safety and efficacy of 6 different acute stroke treatment strategies using data from the English language literature. After accounting for baseline differences between studies, we did not find a significant difference between treatment groups in functional outcome. IV tPA is the most well-studied acute stroke therapy and remains the standard of care for acute stroke. This study supports the need for further research investigating the role of endovascular therapies for acute stroke. Randomized clinical trials are needed to determine the efficacy of alternative reperfusion strategies. Participation in ongoing clinical trials is strongly encouraged. For each trial and treatment option, we calculated good outcomes (mRS≤2) as a proportion of all treated cases with follow-up. Series in which the threshold between mRS 2 & 3 was unclear were excluded. A second set of data were calculated as a proportion of patients surviving treatment. Pooled values of good outcomes were calculated meta-analytically for each treatment option. A oneway ANOVA was performed with Bonferroni correction for post hoc pair-wise comparisons.
